Biofrontera stock news: Roth Capital sees a 300% upside

By:
on Nov 24, 2021
Listen
  • Roth Capital's Jonathan Aschoff initiated Biofrontera Inc at "buy" with a PT of $20.
  • He expects higher Ameluz sales in the U.S. to serve as a catalyst for the BFRI stock.
  • Biofrontera stock gained nearly 50% on the strongly bullish call this morning.

Follow Invezz on Telegram, Twitter, and Google News for instant updates >

Shares of Biofrontera Inc (NASDAQ: BFRI) jumped nearly 50% on Wednesday after Roth Capital said the stock is ready for a massive rally up.

Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.

Analyst Jonathan Aschoff sees upside to $20

Copy link to section

On Wednesday, Roth Capital’s Jonathan Aschoff assumed coverage of the BFRI stock with a “buy” rating and a price target of $20 that represents another 300% increase on top of today’s sharp surge that added millions to its market capitalization that now stands at $56.50 million.

Biofrontera is committed to increasing Ameluz sales in the United States, which will serve as a catalyst fuelling the BFRI stock, the analyst wrote. He also sees Biofrontera’s clinical data for Ameluz as “superior to peers”.

Biofrontera Inc is scheduled to report its financial results for the fiscal third quarter on November 30th.

Where to buy BFRI stock before it skyrockets

Copy link to section

Plus500

Copy link to section

Plus500 is a leading provider of Contracts for Difference (CFDs), delivering Leveraged trading on +2,000 financial instruments, including Forex, Commodities, Indices, Shares and Options.

Register with Plus500 instantly

eToro

Copy link to section

eToro is a multi-asset investment platform with more than 2000 assets, including FX, stocks, ETF’s, indices and commodities. eToro users can connect with, learn from, and copy or get copied by other users. Buying stocks on eToro is free and you can invest with as little as $50.

Register with eToro instantly

A brief overview of Biofrontera Inc

Copy link to section

Founded in 1977, Biofrontera is a biopharmaceutical firm focused on medical cosmetics and dermatological drugs.

The Massachusetts’ headquartered company has been marketing Ameluz for Actinic Keratosis in the U.S. since 2016 after successfully launching it in Europe in 2012. Biofrontera’s other offerings include the dermo-cosmetics series Belixos and Xepi for Impetigo.

As of writing, a little under 200 million shares have been traded today because of the Biofrontera stock news versus BFRI average daily trading volume of only 1.7 million. Biofrontera Inc listed on the Nasdaq Stock Exchange late last month at a per-share price of $4.41.

Ad

Want easy-to-follow crypto, forex & stock trading signals? Make trading simple by copying our team of pro-traders. Consistent results. Sign-up today at Invezz Signals.

Learn more
USA Health & pharma North America Stock Market World